1976results about How to "Relief the pain" patented technology

A facet joint replacement system having an elongate rod and a polyaxial screw having a groove therein, wherein the rod is slidably received within the groove of the polyaxial screw.

The invention generally concerns a spine stabilization system having one or more flexible elements having an opening or slit. The flexible element may be integrally formed in a rod having ends capable of receiving fasteners. The flexible element may limit rotation, flexion-extension, or lateral bending of the spine. The slit or opening may form helical pattern on the rod, and more than one slit or opening may be provided. The flexible element may be conformable to the natural spinal movement.

A system for flexibly stabilizing a vertebral motion segment by connecting a first vertebra and a second vertebra is disclosed. The system includes an elongate connection element with end portions interconnected by a flexible coupling member. The system includes first and second attachment portions for connecting the connection element to the vertebrae. A first resilient member is positioned between the first end portion and the first attachment portion, and a second resilient member is positioned between the first attachment portion and the second attachment portion. The system is designed such that the second resilient member is compressed when the first and second attachment portions move towards each other, and the first resilient member is compressed when the first and second attachment portions extend away from each other.

A liquid composition applied transdermally for relief of pain comprising alcohol in an amount by weight of about 57 to about 91 percent; glycerin in an amount by weight of about 1 to about 12 percent; an analgesic agent in an amount by weight of about 2 to about 28 percent, the analgesic agent comprising a derivative of salicylic acid; methylsulfonylmethane in an amount by weight of about 0.02 to 5 percent; and emu oil in an amount by weight of about 0.01 to 3 percent, the liquid composition permeating skin to relieve pain. The composition further comprising, as an additional feature, aloe vera in an amount by weight of at least about 0.05 percent and having an amount by weight of about 0.05 to 4 percent. The composition features transdermal pain relief such that a patient can apply the analgesic agent directly to an area of pain without such side effects as stomach irritation which is normally associated with aspirin. The composition may be sprayed or rolled directly onto the painful area. Because of the unique formula, the composition is safe to vital internal organs, requires no mixing before use, and is shelf stable for marketing purposes.

An apparatus for treatment of tissue within a body requiring thermotherapy includes a catheter to be inserted into a bodily conduit, an energy-emitting source disposed within the catheter, a compression balloon surrounding the energy-emitting source where the compression balloon has an inflated diameter that is greater than that of the bodily conduit in a relaxed state and an outside surface of the balloon is coated with one of gene modifiers and drug or medication, and means for activating the energy-emitting source to radiate energy to heat the drug-coated compression balloon and tissue to be treated whereby the heated drug-coated compression balloon effectively delivers the one of the gene modifiers and drug or medication to a target area of the diseased tissue. In addition, methods for using the above apparatus to treat diseased tissue are disclosed.

Sustained release compositions comprising a drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.

A system and method for approaching the intervertebral disc through a percutaneous insertion from the back of a patient for thermal or electromagnetic treatment of an intervertebral disc, includes an elongated probe member having a guidable region adjacent its distal end with an undulating groove defined in its outer surface. The undulating groove is dimensioned to facilitate bending of the guidable region in at least one radial direction of movement relative to a longitudinal axis of the thermal probe. Preferably, the guidable region includes a plurality of undulating grooves, whereby adjacent undulating grooves are longitudinally spaced with respect to each other. The undulating grooves each define a sinusoidal configuration which may be arranged about an undulating axis extending in oblique relation to the longitudinal axis. The guidable region also includes a longitudinally extending backbone which resists bending of the guidable region in a radial direction of movement. The apparatus may also include a cannula to facilitate introduction of the thermal probe into the intervertebral disc. The cannula includes an arcuate end portion dimensioned to arrange the guidable region of the thermal probe at a desired orientation within the annulus fibrosis.

A pharmaceutical formulation for delayed release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.

The present invention provides compositions and methods for relieving pain at a site in a human or animal in need thereof by administering at a discrete site in a human or animal in need thereof a dose of capsaicin in an amount effective to denervate a discrete site without eliciting an effect outside the discrete location, the dose of capsaicin ranging from 1 μg to 3000 μg.

A preferably non-electrical nerve communication enhancement tool that sends specific, pre-timed, controlled vibrational and/or acoustical stimulation frequencies to the body to enhance nerve communication for the purpose of assisting in proper function of skeletal muscle, smooth muscle, sympathetic and parasympathetic nervous systems, and facilitating rapid and improved cerebellar timing circuit and related cerebellar learning mechanism pathways such as the inferior olivary-Purkinje-Thalamus cell system and other similar neuronal pools, to improve muscle memory, coordinated functional neuron-musculo-skeletal performance improvement, enhance blood flow, increased range of motion, flexibility, strength and dexterity, neuromuscular re-education, muscle tone recovery, pain modulation, improved eye-hand coordination, gait improvement, balance and stability gains, kinetic chain integration, neurological performance enhancement, sensory dysfunction reduction, and improvement in mental and cognitive function.

A joint support and subchondral support system for providing structural and dampening support to damaged subchondral bone in generalized or discrete arthritis includes a contoured, porous plate having a variable shaped inner surface, outer surface, and peripheral surface of variable thickness extending between the inner surface and the outer surface, suitable for insertion within the subchondral bone. The inner surface, outer surface and peripheral surface each have a concave portion and a convex portion. A guide pin hole or slot is located within the contoured, porous plate to aid in insertion and placement of the plate over at least one corresponding guide pin within the subchondral bone. The joint support and subchondral support system of the present invention is applicable to many parts of the joint as any area with cartilage disease has an adjoining subchondral component.

A removable ball of the foot insert for placement into footwear at a position in correspondence with a forefoot portion of the footwear includes a substantially planar member made from a viscoelastic gel, the planar member including a lower surface and an upper surface, and a plurality of parallel, spaced apart, sinusoidally shaped spring walls formed from a viscoelastic gel and extending from the lower surface of the planar member at a predetermined area corresponding to a ball of the foot when the insert is inserted into the footwear, for separating bones of second and third metatarsals of the foot, the spring walls having heights that generally decrease outwardly from a center of the predetermined area, and the viscoelastic gel of the planar member having a hardness greater than a hardness of the viscoelastic gel of the spring walls.

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R₁ is OSO₂CF₃, OSO₂CH₃, SOR₃, SO₂R₃, COR₃, NO₂, or CONHR₃ and when X is CH or C R₁ may also be CF₃, CN, F, Cl, Br, or I; R₂ is a C₁-C₄ alkyl, an allyl, CH₂SCH₃, CH₂CH₂OCH₃, CH₂CH₂CH₂F, CH₂CF₃, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or —(CH₂)—R₄; R₃ is a C₁-C₃ alkyl CF₃, or N(R₂)₂; R₄ is a C₃-C₆ cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed

According to one embodiment, a system for neurological stimulation of peripheral nerve fibers to treat low back pain is provided. The system includes stimulation electrodes adapted to be implanted in tissue proximate a network of peripheral nerve fibers located in and innervating a painful region of the low back area and to deliver electrical stimulation pulses to the network of peripheral nerve fibers located in and innervating the painful region of the low back area. The system also includes a stimulation source adapted for implantation into the person's body and operable to generate electrical stimulation pulses for transmission to the electrodes for delivery to the network of peripheral nerve fibers located in and innervating the painful region of the low back area to relieve pain in the painful region of the low back area.

The invention provides a weaving finishing agent with the functions of emitting far infrared ray, generating air negative ion, resisting bacterium and retaining moisture, which has positive roles to human body health, belonging to the functional textile technology field. The invention further provides the socks applying the weaving finishing agent, which achieves the functions of warming, killing and resisting bacterium, retaining skin moisture, preventing skin seasoning check, promoting blood circulation, promoting metabolism and alleviating fatigue and ache.

Placement of a silicone tube in the cerebral aqueduct and the transmission of red light through it, resulting in the irradiation and consequent biostimulation of the adjacent periaqueductal gray, thereby causing the release of endorphins therefrom and pain relief.

The method disclosed herein entails spinal cord stimulation via electrodes placed directly into the spinal cord. Electrodes are placed directly into the dorsal horn, dorsal column, spinothalamic tract, nucleus cuneatus, nucleus gracilis, spinal tract of V, or spinal nucleus of V (nucleus caudalis) depending on the source of pain. This “intramedullary” stimulation “jams” or otherwise prevents the pain signal from being transmitted. The placement of the electrodes is accomplished through an open surgical procedure in which the dura is opened to allow the surgeon direct access to the spinal cord. In the case of SCI (or disease), the electrodes are positioned in the dorsal horn of the spinal cord within several dermatomal segments of the lesion site. Stimulation with intramedullary electrodes can be used to treat other types of pain where stable stimulation of the dorsal columns (and the analogous structures for the face), or their nuclear counterparts (nucleus cuneatus, nucleus gracilis, nucleus caudalis) should relieve pain. Stimulation of the spinothalamic tract may also be achieved by intramedullary placement of electrodes. The method provides a means to stimulate the targeted area directly, creating a stable means of stimulating the desired area, and decreasing stimulation of other structures.

The present invention is an apparatus having a stabilizing device, at least two signal applicators, and a signal generator for surface electrical stimulation and stabilization to treat disorders of the joints.